Abstract
Although the androgen receptor (AR)3is often co-expressed with the estrogen receptor (ER)and progesterone receptor (PR) in human breast tumors,its role in breast cancer is poorly understood. Specific growth stimulatory and inhibitory actions ofandrogens have been described in human breast cancercell lines. The mechanisms by which androgens exertthese contrasting growth effects are unknown. A commonly utilized second line therapy for the treatmentof advanced breast cancer is high dosemedroxyprogesterone acetate (MPA). Although MPA, asynthetic progestin, was thought to act exclusivelythrough the PR, the androgenic side-effects observed in womentaking MPA suggest that its action may also be mediatedin part by the AR. In support of this hypothesis, thelevel of AR measured by radioligand binding in primary breast tumors was correlated with theduration of response to MPA treatment following failureof tamoxifen therapy. Recent data suggest that thepresence of structurally altered AR in breast cancers may account for unresponsiveness to MPA in someof these cases. Further studies are warranted todetermine the role of AR mediated pathways in regulatingbreast tumor growth. In particular, identification of androgen-regulated genes may lead to newpossibilities for the hormonal treatment of breastcancer.
Similar content being viewed by others
References
S. M. Thorpe and C. Rose (1986). Oestrogen and progesterone receptor determinations in breast cancer; technology and biology. Cancer Surveys 5:505-525.
C. R. Wenger, S. Beardslee, M. A. Owens, G. Pounds, T. Oldaker, P. Vendely, M. R. Pandian, D. Harrington, G. M. Clark, and W. L. McGuire (1993). DNA Ploidy, S-Phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res. Treat. 28:9-26.
M. F. Pichon, P. Broet, H. Magdelenat, J. C. Delarue, F. Spyr-atos, J. P. Basuyan, S. Saez, A. Rallet, P. Courriere, R. Millon, and B. Asselain (1996). Prognostic value of steroid receptors after long term follw-up of 2257 operable breast cancers. Brit. J. Cancer 73:1545-1551.
O. A. Lea, S. Kvinnsland, and T. Thorsen (1989). Improved measurement of androgen receptors in human breast cancer. Cancer Res. 49:7162-7167.
N. Kimura, A. Mizokami, T. Oonuma, H. Sasano, and H. Nagura (1993). Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. J. Histochem. Cytochem. 41:671-678.
J. A. Soreide, O. A. Lea, J. E. Varhaug, A. Skarstein, and S. Kvinnsland (1992). Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur. J. Surg. Oncol. 18:112-118.
V. Kuenenboumeeste r, T. H. Vanderkwast, W. L. Vanputten, C. Claassen, B. Vanooijen, and S. C. Henzenlogmans (1992). Immunohistochem ical determination of androgen receptors in relation to estrogen and progesterone receptors in female breast cancer. Int. J. Cancer 52:581-584.
J. J. Isola (1993). Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J. Pathol. 170:31-35.
R. J. Santen, A. Manni, H. Harvey, and C. Redmond (1990). Endocrine treatment of breast cancer in women. Endocrine Rev. 11:221-265.
D. C. Tormey, M. E. Lippman, B. K. Edwards, and J. G. Cassidy (1983). Evaluation of Tamoxifen doses with and with out fluoxymesterone in advanced breast cancer. Ann. Intern. Med. 98:139-144.
C. L. Clarke and R. L. Sutherland (1990). Progestin regulation of cellular proliferation. Endocrine Rev. 11:266-301.
F. A. Teulings, H. A. van Gilse, M. S. Henkelman, H. Portengen, and J. Alexieva-Figusch (1980). Estrogen, androgen, glucocor-ticoid, and progesterone receptors in progestin-induced regression of human breast cancer. Cancer Res. 40:2557-2561.
S. Lundgren, P. E. Lonning, E. Utaaker, A. Aakvaag, and S. Kvinnsland (1990). Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer—I. General findings. J. Steroid Biochem. 36:99-104.
D. Chalbos, D. Haagensen, T. Parish, and H. Rochefort (1987). Identfication and androgen regulation of two proteins released by T-47D human breast cancer cells. Cancer Res. 47:2787-2792.
R. Poulin, D. Baker, D. Poirier, and F. Labrie (1989). Androgen and glucocorticoid receptor-mediate d inhibition of cell prolifer-ation by medroxyprogester one acetate in ZR-75-1 human breast cancer cells. Breast Cancer Res. Treat. 13:161-172.
R. Hackenberg, T. Havighorst, A. Filmer, A. H. Nia, and K. D. Schulz (1993). Medroxyprogest erone acetate inhibits the proliferation of estrogen-receptor and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor. Breast Cancer Res. Treat. 25:217-224.
R. Hackenberg, J. Hofmann, F. Holzel, and K. D. Schulz (1988). Stimulatory effects of androgen and antiandrogen on the in vitro proliferation of human mammary carcinoma cells. J. Cancer Res. Clin. Oncol. 114:593-601.
R. Poulin, D. Baker, and F. Labrie (1988). Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res. Treat. 12:213-225.
R. Hackenberg, S. Lüttchens, J. Hofmann, R. Kunzmann, F. Hölzel, and K. D. Schulz (1991). Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Res. 51:5722-5727.
R. L. Sutherland, R. E. Hall, G. Y. Pang, E. A. Musgrove, and C. L. Clarke (1988). Effect of medroxyprogeste rone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res. 48:5084-5091.
K. B. Horwitz, D. T. Zava, A. K. Thilagar, E. M. Jensen, and W. L. McGuire (1978). Steroid receptor analyses of nine human breast cancer cell lines. Cancer Res. 38:2434-2437.
S. Dauvois, C. S. Geng, C. Levesque, Y. Merand, and F. Labrie (1991). Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res. 51:3131-3135.
S. N. Birrell, J. M. Bentel, T. E. Hickey, C. Ricciardelli, M. A. Weger, D. J. Horsfall, and W. D. Tilley (1995). Androgens Induce Divergent Proliferative Responses In Human Breast Cancer Cell Lines. J. Steroid Biochem. Mol. Biol. 52:459-467.
C. Chang, J. Kokontis, and S. Liao (1988). Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240:324-326.
D. B. Lubahn, D. R. Joseph, P. M. Sullivan, H. F. Willard, F. S. French, and E. M. Wilson (1988). Cloning of human androgen receptor complementary DNA and localization to the x chromosome. Science 240:327-330.
W. D. Tilley, M. Marcelli, J. D. Wilson, and M. J. McPhaul (1989). Characterization and expression of a cDNA encoding the human androgen receptor. Proc. Natl. Acad. Sci. USA 86:327-331.
R. E. Hall, W. D. Tilley, M. J. McPhaul, and R. L. Sutherland (1992). Regulation of androgen receptor gene expression by steroids and retinoic acid in human breast-cancer cells. Int. J. Cancer 52:778-784.
R. Hackenberg, T. Hawighorst, A. Filmer, E. P. Slater, K. Bock, and M. Beato (1992). Regulation of androgen receptor mRNA and protein level by steroid hormones in human mammary cancer cells. J. Steroid Biochem. Mol. Biol. 43:599-607.
R. Poulin, J. Simard, C. Labrie, L. Petitclerc, M. Dumont, and L. Lagace (1989). Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology 125:392-399.
D. T. Zava and W. L. McGuire (1977). Estrogen receptors in androgen-induced breast tumor regression. Cancer Res. 37:1608-1610.
R. Hackenberg, J. Hofmann, G. Wolff, F. Holzel, and K. D. Schulz (1990). Down-regulation of androgen receptor by pro-gestins and interference with estrogenic or androgenic stimula tion of mammary carcinoma cell growth. J. Cancer Res. Clin. Oncol. 116:492-498.
F. Labrie, R. Poulin, J. Simard, H. F. Zhao, C. Labrie, and S. Dauvois (1990). Interactions between estrogens, androgens, progestins, and glucocorticoids in ZR-75-1 human breast cancer cells. Ann. N. Y. Acad. Sci. 595:130-148.
R. Poulin, D. Baker, D. Poirier, and F. Labrie (1991). Multiple actions of synthetic ‘progestins’ on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids. Breast Cancer Res. Treat. 17:197-210.
R. E. Hall, S. N. Birrell, W. D. Tilley, and R. L. Sutherland (1994). MDA-MB-453, An androgen-responsive human breast carcinoma cell line with a high level of androgen receptor expression. Eur. J. Cancer 30A:484-490.
S. N. Birrell, J. M. Bentel, D. J. Horsfall, and W. D. Tilley (1996). Androgen receptor expression and medroxyprogeste r-one acetate therapy in human breast cancer. Proc. Amer. Assoc. Cancer Res. 37:237.
T. Ojasoo, J. P. Raynard, and J. C. Dore (1994). Affiliations among steroid receptors as revealed by multivariate analysis of steroid binding data. J. Steroid Biochem. Mol. Biol. 48:31-46.
S. N. Birrell, D. M. Roder, J. M. Bentel, D. J. Horfall, and W. D. Tilley (1995). Medroxyprogesteron e acetate therapy in advanced breast cancer: The prognositic value of Androgen Receptor expression. J. Clin. Oncol. 13:1572-1577.
D. F. Hull, III, G. M. Clark, C. K. Osborne, G. C. Chamness, W. A. Knight, III, and W. L. McGuire (1983). Multiple estrogen receptor assays in human breast cancer. Cancer Res. 43:413-416.
G. E. Gross, G. M. Clark, G. C. Chamness, and W. L. McGuire (1984). Multiple progesterone receptor assays in human breast cancer. Cancer Res. 44:836-840.
C. A. Encarnacion, D. R. McGuire, W. L. Clark, S. A. W. Fuqua, and C. K. Osborne (1993). Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat. 26:237-246.
S. R. D. Johnston, G. Saccanijotti, I. E. Smith, J. Salter, J. Newby, and M. Coppen (1995). Changes in estrogen receptor, progesterone receptor, and ps2 expression in tamoxifen-resis-tant human breast cancer. Cancer Res. 55:3331-3338.
M. L. Graham, J. A. Smith, P. B. Jewett, and K. B. Horwitz (1992). Heterogeneity of progesterone receptor content and remodeling by tamoxifen characterize subpopulations of cul-tured human breast cancer cells: analysis by quantitative dual parameter flow cytometry. Cancer Res. 52:593-602.
W. D. Tilley, S. S. Lim-Tio, D. J. Horsfall, J. O. Aspinall, V. R. Marshall, and J. M. Skinner (1994). Detection of discrete androgen receptor epitopes in prostate cancer by immunostain-ing-measurement by color video image analysis. Cancer Res. 54:4096-4102.
C. M. Wilson and M. J. McPhaul (1994). A and B forms of the androgen receptor are present in human genital skin fibroplasts. Proc. Natl. Acad. Sci. USA 91:1234-1238.
C. A. Quigley, A. Debellis, K. B. Marschke, M. K. Elawady, E. M. Wilson, and F. S. French (1995). Androgen receptor defects—historical, clinical, and molecular perspectives. Endocrine Rev. 16:271-321.
J. D. Graham, C. Yeates, R. L. Balleine, S. S. Harvey, J. S. Milliken, A. M. Bilous, and C. L. Clarke (1995b). Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res. 55:5063-5068.
J. P. Elo, L. Kvist, K. Leinonen, V. Isomaa, P. Henttu, and O. Lukkarinen (1996). Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estra-diol. J. Clin. Endocrinol. Metabol. 80:3494-3500.
X. Zhu, A. A. Daffada, C. M. Chan, and M. Dowsett (1997). Identification of an exon 3 deletion-splice variant androgen receptor mRNA in human breast cancer. Int. J. Cancer (inpress).
L. V. Nazereth and N. L. Weigel (1996). Activation of the human androgen receptor through a protein kinase a signaling pathway. J. Biol. Chem. 271:19900-19907.
Z. Culig, A. Hobisch, M. V. Cronauer, C. Radmayr, J. Trapman, A. Hittmair, G. Bartsch, and H. Klocker (1994). Androgen receptor activation in prostate tumor cell lines by insulin-like growth factor-I, Keratinocyte Growth Factor, and epidermal growth factor. Cancer Res. 54:5474-5478.
Rights and permissions
About this article
Cite this article
Birrell, S.N., Hall, R.E. & Tilley, W.D. Role of the Androgen Receptor in Human Breast Cancer. J Mammary Gland Biol Neoplasia 3, 95–103 (1998). https://doi.org/10.1023/A:1018730519839
Issue Date:
DOI: https://doi.org/10.1023/A:1018730519839